GlassScriptPhysician profile
Sylveena E Ali
NPI 1134174931
$2,230.00
in general payments reported to CMS, 2019-2025
24 companies · $558 in 2025
The $558 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $100 · 2023: $649 · 2024: $700 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,900 · Travel and Lodging: $7.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,900.04 |
| Travel and Lodging | $7.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $485.64 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $403.13 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $226.10 | 2023-2025 | |
| Gilead Sciences, INC. | $189.39 | 2024-2025 | |
| Viiv Healthcare Company | $135.93 | 2024-2025 | Apretude |
| Lundbeck LLC | $125.00 | 2021 | |
| Exact Sciences Corporation | $123.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi Pasteur INC. | $82.23 | 2023-2025 | |
| Medtronic, INC. | $75.00 | 2025 | Venaseal |
| Coopersurgical, INC. | $43.28 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.29 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $38.49 | 2023 | Eliquis |
| Abbvie INC. | $34.48 | 2023 | Liletta |
| Bioventus LLC | $30.00 | 2025 | Exogen Ultrasound Bone Healing System |
| Amgen INC. | $25.98 | 2024 | Krystexxa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.81 | 2021 | |
| Corcept Therapeutics | $22.26 | 2024 | Korlym |
| Merck Sharp & Dohme LLC | $21.39 | 2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Novartis Pharmaceuticals Corporation | $19.16 | 2022 | |
| Organon LLC | $18.84 | 2021 | |
| Glaxosmithkline, LLC. | $18.83 | 2023 | Shingrix |
| Cranial Technologies, INC | $18.77 | 2025 | Doc Band |
| Bayer Healthcare Pharmaceuticals INC. | $15.18 | 2023 | |
| Abbott Laboratories | $14.30 | 2024 | Proclaim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylveena Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.